Dr. Ronan J. Kelly

Dr. Kelly received his medical degree from the Royal College of Surgeons in Ireland in 1998. He completed his internship, residency and oncology fellowship from the Royal College of Physicians in Ireland in 2007. Dr. Kelly completed a second fellowship in medical oncology at the National Cancer Institute (NCI) in Bethesda MD from 2007–2009 and continued as a clinical researcher in thoracic oncology at the NCI until moving to Johns Hopkins in 2011. At Johns Hopkins, Dr. Kelly was the director of the gastroesophageal cancer therapeutics program and also served as the director of global oncology for Johns Hopkins International. Dr. Kelly was recruited as the Director of Oncology for the Charles A. Sammons Cancer Center and the Chief of Oncology for the North Texas Division of the BSWH system in 2018. Dr. Kelly performs translational and clinical research encompassing the discovery and the development of new targeted and immunotherapeutic approaches in the prevention and treatment of gastroesophageal cancer and lung cancer and he is the International principal investigator on a number of global phase II/III clinical trials in these disease areas. In addition he is leading efforts nationally and internationally to design quality metrics for solid tumors and implementing value-based algorithms to help bend the cost curve in the United States. At the Charles A. Sammons Cancer Center he also helps to co-lead the Innovative Clinical Trials Center which investigates novel therapeutics across a range of tumor types. He serves as the co-chair of the International Association for the Study of Lung Cancer (IASLC) and the American Society of Clinical Oncology (ASCO) taskforce working to improve the quality of care received by lung cancer patients worldwide. He is an active member of ASCO and the Eastern Cooperative Oncology group. He is a founding member of the International Quality Oncology Taskforce in ASCO and serves on the ASCO measures taskforce, the clinical practice committee and the lung cancer quality taskforce. He has authored and co-authored over 150 peer-reviewed publications, abstracts and book chapters, and contributed his work to many prominent healthcare journals. Dr. Kelly’s leadership of oncology services spans Baylor Scott & White’s footprint in the Dallas-Fort Worth area, which includes Baylor University Medical Center—the System’s North Texas flagship hospital and one of the largest cancer hospitals in the nation—as well as a network of 11 Baylor Charles A. Sammons Cancer Centers throughout Texas. Publications.

Dr. Kelly is highly rated in 9 conditions, according to our data. His top areas of expertise are Esophageal Cancer, Gastroesophageal Junction Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreaticoduodenectomy, and Tissue Biopsy.

His clinical research consists of co-authoring 107 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.